Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer (Q33257718)

24 July 2017

Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer (English)

1 reference

24 July 2017

metastatic breast cancer

1 reference

1 reference

1 reference

Laura Orlando

1

1 reference

24 July 2017

Anna Cardillo

2

1 reference

24 July 2017

Raffaella Ghisini

3

1 reference

24 July 2017

Andrea Rocca

4

1 reference

24 July 2017

Alessandra Balduzzi

5

1 reference

24 July 2017

Rosalba Torrisi

6

1 reference

24 July 2017

Giulia Peruzzotti

7

1 reference

24 July 2017

Aron Goldhirsch

8

1 reference

24 July 2017

Elisabetta Pietri

9

1 reference

24 July 2017

Marco Colleoni

10

1 reference

24 July 2017

language of work or name

English

0 references

publication date

15 September 2006

1 reference

24 July 2017

1 reference

24 July 2017

6

1 reference

24 July 2017

225

1 reference

Creative Commons Attribution 2.0 Generic

24 July 2017

start time

15 September 2006

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

exact match

https://scigraph.springernature.com/pub.10.1186/1471-2407-6-225

0 references

cites work

Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1579231

Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1579231

Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1579231

Differential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimers

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1579231

HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1579231

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1579231

'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1579231

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1579231

Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1579231

HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1579231

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1579231

The neu oncogene encodes an epidermal growth factor receptor-related protein

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1579231

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1579231

Chemotherapy induces regression of brain metastases in breast carcinoma.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1579231

21 June 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-225

Tumour biology: herceptin acts as an anti-angiogenic cocktail.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-225

Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-225

Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-225

Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-225

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-225

Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-225

Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-225

The effect of trastuzumab/docatexel combination on breast cancer angiogenesis: dichotomus effect predictable by the HIFI alpha/VEGF pre-treatment status?

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1579231

Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels

31 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/16978400

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

ERBB2 oncogene in human breast cancer and its clinical significance

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/16978400

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1471-2407-6-225

1 reference

Dimensions Publication ID

24 July 2017

0 references

1 reference

24 July 2017

1 reference